NASDAQ:IOVA Iovance Biotherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.47 +0.43 (+3.89%) (As of 07/1/2022 08:44 PM ET) Add Compare Share Today's Range$10.94▼$11.6250-Day Range$6.38▼$16.8852-Week Range$6.18▼$27.96Volume4.14 million shsAverage Volume3.53 million shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$26.10 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Iovance Biotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside127.6% Upside$26.10 Price TargetShort InterestHealthy11.91% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.29Based on 5 Articles This WeekInsider TradingAcquiring Shares$74.84 K Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($2.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.53 out of 5 starsMedical Sector82nd out of 1,412 stocksBiological Products, Except Diagnostic Industry12th out of 215 stocks 4.4 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.10, Iovance Biotherapeutics has a forecasted upside of 127.6% from its current price of $11.47.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.91% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 4.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 67.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -1.23. Previous Next 1.8 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Iovance Biotherapeutics this week, compared to 1 article on an average week.Search InterestOnly 31 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,840.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Iovance Biotherapeutics is held by insiders.Percentage Held by Institutions99.07% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.49) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Iovance Biotherapeutics (NASDAQ:IOVA) StockIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock News HeadlinesJuly 1, 2022 | markets.businessinsider.com7 Analysts Have This to Say About Iovance BiotherapeuticsJune 27, 2022 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 16, 2022 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 4.7% June 13, 2022 | finance.yahoo.comIovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of DirectorsJune 12, 2022 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Trading 3.4% Higher June 9, 2022 | americanbankingnews.comIovance Biotherapeutics' (IOVA) "Buy" Rating Reaffirmed at JMP SecuritiesJune 9, 2022 | americanbankingnews.comModerna (NASDAQ:MRNA) & Iovance Biotherapeutics (NASDAQ:IOVA) Head to Head ComparisonJune 6, 2022 | finance.yahoo.comDown More Than 40%: Insiders Call a Bottom in These 2 StocksJune 3, 2022 | seekingalpha.comIovance climbs over 15% after multiple insider purchasesMay 30, 2022 | nasdaq.comIovance Biotherapeutics Now the Least Expensive vs. Bitcoin This YearMay 27, 2022 | barrons.comIovance Stock Tumbles on Cancer Data. Analysts Say the Selloff Went Too Far.May 27, 2022 | finance.yahoo.comWhy Iovance Biotherapeutics Was Halved TodayMay 27, 2022 | finance.yahoo.comIovance (IOVA) Down After Announcing Data From Melanoma StudyMay 26, 2022 | seekingalpha.comIovance slips as objective response rate reaches 29% for melanoma candidateMay 26, 2022 | finance.yahoo.comIovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced MelanomaMay 26, 2022 | finance.yahoo.comIovance's stock slides 40% after sharing data about its melanoma therapyMay 6, 2022 | finance.yahoo.comIovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on TrackApril 27, 2022 | finance.yahoo.comIovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual MeetingApril 20, 2022 | seekingalpha.comIovance: Onward To ApprovalApril 7, 2022 | finance.yahoo.comHere's The Bullish Sign From Iovance That Could Signal Its TurnaroundApril 6, 2022 | finance.yahoo.comIovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo TherapyApril 5, 2022 | seekingalpha.comIovance receives positive feedback from FDA for metastatic melanoma therapyMarch 17, 2022 | morningstar.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | MorningstarMarch 15, 2022 | tmcnet.comIovance Biotherapeutics' Investigational New Drug Application (IND) AllowedMarch 8, 2022 | finance.yahoo.comIovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual MeetingSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees319Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$26.10 High Stock Price Forecast$43.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+127.6%Consensus RatingModerate Buy Rating Score (0-4)2.88888888888889 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-342.25 million Net MarginsN/A Pretax MarginN/A Return on Equity-54.79% Return on Assets-45.37% Debt Debt-to-Equity RatioN/A Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book2.90Miscellaneous Outstanding Shares157,168,000Free Float145,223,000Market Cap$1.80 billion OptionableOptionable Beta0.46 Iovance Biotherapeutics Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Iovance Biotherapeutics stock. View analyst ratings for Iovance Biotherapeutics or view top-rated stocks. What is Iovance Biotherapeutics' stock price forecast for 2022? 9 Wall Street analysts have issued 1 year target prices for Iovance Biotherapeutics' shares. Their IOVA stock forecasts range from $13.00 to $43.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $26.10 in the next twelve months. This suggests a possible upside of 127.6% from the stock's current price. View analysts' price targets for Iovance Biotherapeutics or view top-rated stocks among Wall Street analysts. How has Iovance Biotherapeutics' stock price performed in 2022? Iovance Biotherapeutics' stock was trading at $19.09 at the start of the year. Since then, IOVA stock has decreased by 39.9% and is now trading at $11.47. View the best growth stocks for 2022 here. When is Iovance Biotherapeutics' next earnings date? Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Iovance Biotherapeutics. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.06. The biotechnology company earned $12 million during the quarter. The company's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share. View Iovance Biotherapeutics' earnings history. Who are Iovance Biotherapeutics' key executives? Iovance Biotherapeutics' management team includes the following people: Dr. Frederick G. Vogt Esq., J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec. (Age 48, Pay $752.81k)Mr. Jean-Marc Bellemin M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 50, Pay $623.6k)Dr. Igor P. Bilinsky, Chief Operating Officer (Age 49, Pay $577.35k)Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 55, Pay $649.13k)Ms. Sara Pellegrino, VP of Investor Relations & PRMs. Tracy Winton, Sr. VP of HRMr. Howard B. Johnson M.B.A., Chief Bus. Officer (Age 62)James Ziegler, Sr. VP of CommercialMr. Madan Jagasia, Sr. VP of Medical AffairsDr. Raj K. Puri M.D., Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine Who are some of Iovance Biotherapeutics' key competitors? Some companies that are related to Iovance Biotherapeutics include Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Novavax (NVAX), Ginkgo Bioworks (DNA), Denali Therapeutics (DNLI), Ablynx (ABLYF), Vir Biotechnology (VIR), Abcam (ABCM), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX) and Relay Therapeutics (RLAY). View all of IOVA's competitors. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." How do I buy shares of Iovance Biotherapeutics? Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $11.47. How much money does Iovance Biotherapeutics make? Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.80 billion. The biotechnology company earns $-342.25 million in net income (profit) each year or ($2.29) on an earnings per share basis. How many employees does Iovance Biotherapeutics have? Iovance Biotherapeutics employs 319 workers across the globe. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for Iovance Biotherapeutics is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com. This page (NASDAQ:IOVA) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
